MARKET NEWS

Ajinomoto Althea & OmniChem Combine to Form Ajinomoto Bio-Pharma Services
Cerecor to Acquire Ichorion Therapeutics; Transaction Worth $26.6 Million
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials
VisionGate Presents Breakthrough Research on Cell-CT Platform
Cobra Biologics, GE Healthcare & Centre for Process Innovation Collaborate to Advance Gene Therapy
Immutep Enters Into Clinical Trial Collaboration & Supply Agreement With Merck & Pfizer

  FEATURED EDITORIAL

  COMPANY PROFILE

 

 

Ascendia Pharmaceuticals is a speciality contract development and manufacturing (CDMO) company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. We specialize in creating formulation solutions for poorly water-soluble molecules and other challenging pharmaceutical development projects. Using our suite of formulation capabilities and nanoparticle technologies, we can assess the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability. Ascendia formulates products for injection (IV, SC, or IM), transdermal, ophthalmic, or nasal delivery; and both immediate-release and controlled-release products for oral administration. We execute rapid, comprehensive, and cost-effective programs for our clients. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study

Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study

Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).

Brammer Bio Announces Progress on 0-Million Program to Advance Gene Therapies

Brammer Bio Announces Progress on $200-Million Program to Advance Gene Therapies

Brammer Bio recently announced that a 3-year, $200-million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies

Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies

GB Sciences, Inc. and Catalent Pharma Solutions recently announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 10 – API Manufacturing
October 17 – Bioavailability